Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555936 | 0.82 | PNP (0.59) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL11021787 | 0.82 | PNP (0.59) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3759135 | 0.80 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3766542 | 0.80 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21625245 | 0.80 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3766539 | 0.80 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL13788428 | 0.80 | ALDH1A1 (0.53) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL2911996 | 0.79 | ADORA2A (0.60) | LMNATP53HTTSMN1; SMN2DNMT1 | |
| SCHEMBL2911993 | 0.79 | ADORA2A (0.60) | LMNATP53HTTSMN1; SMN2DNMT1 | |
| SCHEMBL13787625 | 0.79 | ADORA2A (0.60) | LMNATP53HTTSMN1; SMN2DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | MSD INTERNATIONAL GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | SLC10A1, PNP, PYGL | PNP 2/4885LMNA 1820/4885TP53 1761/4885 |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | SLC10A1, PNP, PYGL | PNP 2/4885LMNA 1820/4885TP53 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.